We report the final results of the outcome of patients treated with vistusertib in treatment arm B of the National Lung Matrix Trial (NLMT), a large stratified medicine trial in NSCLC, focusing on the cohort of patients whose NSCLC harbour STK11 loss, with or without concomitant KRAS mutations. This evidence concerns the gene STK11 and non-small cell lung carcinoma.